6855 — Ascentage Pharma International Share News
0.000.00%
Last trade - 00:00- HK$11.38bn
- HK$11.63bn
- CNY574.12m
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up
Brief: Ascentage Pharma Group International Posts FY Loss Increased To RMB1,243 Million
Ascentage rises on progress of olverembatinib for blood cancer treatment
Brief: Ascentage Pharma Group International Says Phase III Study Of Olverembatinib Cleared By FDA, EMA
Brief: Ascentage Pharma Group International Posts HY Net Loss Was RMB590.8 Million
Brief: Ascentage Pharma Group International FDA And EMA Clear Phase Iii Study Of Lisaftoclax For Hr-Mds
China's Ascentage Pharma hits 4-week low on discounted share sale
Brief: Ascentage Pharma Group International To Issue Up To 22 Million New Subscription Shares At HK$68.60 Per Share
Brief: Ascentage Pharma Group International Prices 22 Mln Shares At HKD 68.60 Each
Brief: Ascentage Pharma Group International Says China NMPA Approves Ascentage's Lisaftoclax For CLL/SLL
Brief: Ascentage Pharma Group International Says Revenue In 2024 Increased 342% Year-Over-Year
Brief: Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results And Business Updates
Brief: Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation
Brief: Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Takeda-backed Ascentage Pharma falls in Nasdaq debut after discounted $126 mln IPO
Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO (updated)